Literature DB >> 29283500

Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf.

Enrico Luchinat1,2, Sara Chiarella3,4, Mimma Franceschini3,4, Adele Di Matteo5, Maurizio Brunori6, Lucia Banci1,7, Luca Federici3,4.   

Abstract

The tumor suppressor p14arf interacts, in response to oncogenic signals, with the p53 E3-ubiquitin ligase HDM2, thereby resulting in p53 stabilization and activation. In addition, it also exerts tumor-suppressive functions in p53-independent contexts. The activities of p14arf are regulated by the nucleolar chaperone nucleophosmin (NPM1), which controls its levels and cellular localization. In acute myeloid leukemia with mutations in the NPM1 gene, mutated NPM1 aberrantly translocates in the cytosol carrying with itself p14arf that is subsequently degraded, thus impairing the p14arf-HDM2-p53 axis. In this work we investigated the complex between these two proteins by means of NMR and other techniques. We identified a novel NPM1-interacting motif in the C-terminal region of p14arf, which corresponds to its predicted nucleolar localization signal. This motif recognizes a specific region of the NPM1 N-terminal domain and, upon binding, the two proteins form soluble high molecular weight complexes. By NMR, we identified critical residues on both proteins involved in the interaction. Collectively, our data provide a structural framework to rationalize the overall assembly of the p14arf-NPM1 supramolecular complexes. A number of p14arf cancer-associated mutations cluster in this motif and their effect on the interaction with NPM1 was also analyzed.
© 2017 Federation of European Biochemical Societies.

Entities:  

Keywords:  ARF; B23; NPM1; acute myeloid leukemia; cancer target; protein-protein interactions

Mesh:

Substances:

Year:  2018        PMID: 29283500     DOI: 10.1111/febs.14373

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  8 in total

1.  On the relationship status for Arf and NPM1 - it's complicated.

Authors:  Diana M Mitrea; Richard W Kriwacki
Journal:  FEBS J       Date:  2018-03       Impact factor: 5.542

2.  Nucleus-translocated mitochondrial cytochrome c liberates nucleophosmin-sequestered ARF tumor suppressor by changing nucleolar liquid-liquid phase separation.

Authors:  Katiuska González-Arzola; Antonio Díaz-Quintana; Noelia Bernardo-García; Jonathan Martínez-Fábregas; Francisco Rivero-Rodríguez; Miguel Á Casado-Combreras; Carlos A Elena-Real; Alejandro Velázquez-Cruz; Sergio Gil-Caballero; Adrián Velázquez-Campoy; Elzbieta Szulc; María P Gavilán; Isabel Ayala; Rocío Arranz; Rosa M Ríos; Xavier Salvatella; José M Valpuesta; Juan A Hermoso; Miguel A De la Rosa; Irene Díaz-Moreno
Journal:  Nat Struct Mol Biol       Date:  2022-10-11       Impact factor: 18.361

Review 3.  Enzymatic Noncovalent Synthesis.

Authors:  Hongjian He; Weiyi Tan; Jiaqi Guo; Meihui Yi; Adrianna N Shy; Bing Xu
Journal:  Chem Rev       Date:  2020-08-19       Impact factor: 60.622

Review 4.  Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer.

Authors:  Dai Shimizu; Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastrointest Oncol       Date:  2018-06-15

Review 5.  Dual Role of the Alternative Reading Frame ARF Protein in Cancer.

Authors:  Rosa Fontana; Michela Ranieri; Girolama La Mantia; Maria Vivo
Journal:  Biomolecules       Date:  2019-03-04

Review 6.  Nucleophosmin in Its Interaction with Ligands.

Authors:  Ilaria Cela; Adele Di Matteo; Luca Federici
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

Review 7.  The nucleolus, an ally, and an enemy of cancer cells.

Authors:  Dariusz Stępiński
Journal:  Histochem Cell Biol       Date:  2018-08-13       Impact factor: 4.304

8.  The Dundee Resource for Sequence Analysis and Structure Prediction.

Authors:  Stuart A MacGowan; Fábio Madeira; Thiago Britto-Borges; Mateusz Warowny; Alexey Drozdetskiy; James B Procter; Geoffrey J Barton
Journal:  Protein Sci       Date:  2019-11-28       Impact factor: 6.725

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.